Facebook
Twitter
LinkedIn
ForwardThyroid Cancer Roundtable 2024 - From Microcarcinoma to Advanced Management
The treatment of early and advanced thyroid cancer is rapidly changing due to developments in targeted drug therapy and new surgical and minimally invasive approaches. This session will familiarize the learner with the new targeted agents and their appropriate place in the treatment algorithms. It will also explore nuances in surgical therapy, including management of the recurrent laryngeal nerve in invasive disease, and the new technique of radiofrequency ablation therapy for microcarcinomas.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Outline the management strategies of thyroid microcarcinoma, including the use of radiofrequency ablation therapy.
- Identify the appropriate indications and drugs for the treatment of thyroid cancer with RET mutations.
- Describe the use of neoadjuvant targeted therapy and surgery for advanced thyroid cancer.
Brian Burkey, MD, MEd, FACS, is employed by the Cleveland Clinic and has no financial relationships with a commercial interest.
Caitlin McMullen, MD, is employed by Moffitt Cancer Center and received travel compensation from Congreso Chileno de Otorrinolaryngologia.
Mark Zafereo, MD, FACS, is employed by MD Anderson Cancer Center and receives research funding from Eli Lilly and Merck. He serves in a leadership position with American Academy of Otolaryngology -Head and Neck Surgery, Head and Neck Journal and the International Thyroid Oncology Group.
Greg Randolph, MD, FACS, FAZE, is employed by MEEI and receives honorarium compensation from Eisai and Medtronic. He serves in a leadership position with ITOF.
Jennifer Choe, MD, is employed by Vanderbilt University and receives compensation/research funding from Coherus, Genentech and Merck. She also serves on the advisory boards of Coherus, Exelixis and Merck.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.